anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lovenox
Trial phase: Phase 4
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 251
Group description: Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.

Subcutaneous Heparin: 5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
Eligibility criteria:
Inclusion Criteria:

Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP
Patients who would have otherwise been eligible to receive routine post-RP care

Exclusion Criteria:

Active treatment for VTE
Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)
Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
Epidural analgesia
Spinal anesthesia
Participation in a different trial that increases a patient's risk of VTE
Intervention: Lorcaserin
Trial phase: Phase 2
ATC code: A08AA11
SMILES: C[C@H]1CNCCc2ccc(Cl)cc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 118
Group description: 10 mg capsule by mouth, twice a day, for 13 weeks

Lorcaserin: Lorcaserin Capsule
Eligibility criteria:
Inclusion Criteria:

Has a DSM-5 diagnosis of current cocaine use disorder as verified by the Structured Clinical Interview for DSM-5
Is seeking treatment for cocaine use disorder
Is able to understand and provide written informed consent
Has used cocaine on at least 1 day in the last 30 days prior to screening
Has completed all psychological assessments and procedures during the screening period
If female, not pregnant, lactating, unable to conceive OR must agree to use an acceptable method of birth control
Has a total body weight greater than 110 pounds and body mass index greater than 20

Exclusion Criteria:

Contact site for more information
Intervention: Akynzeo
Trial phase: Phase 2
SMILES: C=CC(=CC)c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.O=C1c2cccc3c2C(CCC3)CN1C1CN2CCC1CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.

Netupitant and Palonosetron: 300 mg of netupitant and 0.5 mg of palonosetron
Eligibility criteria:
Inclusion Criteria:

Adults greater than or equal to 18 years old.
Must have a histologically confirmed cancer diagnosis.
Must have refractory CINV defined as nausea and/or vomiting that occurs after the first cycle of chemotherapy despite guideline-based prophylaxis and after first-line rescue medication with either a dopamine receptor antagonist, steroid, and/or benzodiazepine.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
Life expectancy greater than 3 months.
Corrected serum calcium level less than or equal to 10.5 mg/dL.

Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 14 days following completion of therapy.

A) A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

i) Has not undergone a hysterectomy or bilateral oophorectomy; or ii) Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months)

Women of child-bearing potential must have a negative pregnancy test prior to initiating study treatment.
Ability to understand and willingness to sign a written informed consent.

Exclusion Criteria:

Patients with QTc interval greater than 450 ms.
Patients with a known hypersensitivity reaction to 5-HT3 receptor antagonists or NK1 receptor antagonists.
Patients who have taken any medication classified as a strong CYP3A4 inducer within one week of Study Day 1 or 5 halflives (whichever is longer) or use of a strong or moderate CYP3A4 inhibitor within one week of Study Day 1 or 5 halflives (whichever is longer) (see Appendix 2).
Patients with severe hepatic impairment as defined as AST/ALT greater than three times the upper limit of normal, total bilirubin greater than 3 mg/dL, and/or Child-Pugh score >9.
Patients with end-stage renal disease defined as creatinine clearance of <15mL/min and/or diagnosed with Stage 5 chronic kidney disease.
Pregnant or lactating females are excluded from enrollment on this trial.
Patients unable to swallow oral medications. Any other condition that, in the opinion of the investigator, may impact the absorption of oral medications.
Intervention: Naltrexone
Trial phase: Phase 2
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Adverse events during naltrexone
Eligibility criteria:
Inclusion Criteria:

Patients must meet all of the following criteria in order to be eligible for enrollment:

Veteran or otherwise eligible for VA benefits, able to travel to VA Boston

One or more of the following chronic conditions:

osteoarthritis
rheumatoid arthritis
non-axial spondyloarthritis
Average daily pain interference with function (average of the 7 parts of question 9 on the Brief Pain Inventory) rated at least 4 on a scale of 0-10, and no higher than 9
No change in medication in the past 8 weeks made with the expectation of improving pain
No plan to start another medication or a non-pharmacologic treatment regimen likely to affect pain during the next 16 weeks
Age at least 18
Registered for medical care in the VA Boston Healthcare System
Capable of informed consent, and willingness to comply with study procedures, including receipt of weekly phone calls from the study coordinator

Exclusion Criteria:

Any of the following requires exclusion from participation:

Current use of opioids including tramadol
Pregnant, breast feeding, or unwilling to engage in contraceptive practices if sexually active and capable of conceiving
Schizophrenia, bipolar disorder, or poorly controlled depression or anxiety
Previous use of low-dose naltrexone
Back pain described by the patient as greater in severity than arthritic pain in a non-axial location
Significant kidney disease, defined as glomerular filtration rate < 30 ml/min
Liver cirrhosis. There is no specific screening procedure to exclude cirrhosis.
Painful peripheral neuropathy. There is no specific screening procedure.
Plan to have surgery during the next 16 weeks
Inconsistency in self-reporting at the screening visit. BPI, PainDETECT, WOMAC, and PROMIS-29 all contain 0-10 scales of average pain intensity, although the times listed vary from 1-4 weeks. The severity reported on these three scales cannot differ by more than 1.
Other qualitative circumstances that the investigator feels would make the patient a poor candidate for this clinical trial, such as an unstable social situation or unreliable transportation
Intervention: ASPIRIN
Trial phase: Phase 2
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Assessment on aspirin 81mg for 2 weeks.
Eligibility criteria:
Inclusion Criteria:

Alpha-1 antitrypsin deficiency (PiZZ genotype)
40 years of age or older
Evidence of emphysema on CT scan as read by a Radiologist

Exclusion Criteria:

Platelet count < 150,000/dL, history of intracranial hemorrhage or severe GI bleed, use of systemic anticoagulant, physician prescribed use of antiplatelet drug (including aspirin and P2Y12 receptor inhibitors), or known severe liver disease
Immunosuppression by use of medications (including oral prednisone), or those with immunomodulatory disease (organ transplantation, autoimmune conditions or actively-treated malignancy)
Known atrial fibrillation or left ventricular (LV) systolic heart failure
Contraindication to MRI, including pregnancy, weight > 300 lbs (due to weight limits of the machine), those with pacemakers, aneurysm clips, cochlear implants or other implanted electronic devices, or severe claustrophobia;
Chronic renal insufficiency (estimated GFR < 45 L/min/1.73 m2 or self report) due to slightly increased risk of nephrogenic systemic fibrosis from gadolinium administration and aspirin-related renal insufficiency
Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms.
Intervention: Nicorandil
Trial phase: Phase 4
ATC code: C01DX16
SMILES: O=C(NCCO[N+](=O)[O-])c1cccnc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
Eligibility criteria:
Inclusion criteria:

Female
Participants aged 18-70 years
Participants with typical stable angina but without coronary obstruction (defined as coronary occlusion less than (<) 50%) by invasive coronary angiography or coronary computed tomography angiography (CTA) in recent three months
All other long acting cardiovascular disease medicines, including but not limited to aspirin/clopidogrel, calcium channel blockers (CCB), Angiotensin-converting enzyme inhibitors (ACEI)/Angiotensin II Receptor Blockers (ARB), beta-blockers, statins, ivabradine, trimetazidine, et al, should be stable taken for at least two weeks before screening period
For participants who met these four criteria above, MFR will be tested by stress PET. Participants whose MFR <3.0 could be included in the study

Exclusion criteria:

Severe or uncontrolled hypertension (resting Systolic blood pressure [SBP] >=160 millimeter of mercury (mmHg), or resting Diastolic blood pressure [DBP] >=100mmHg at screening period)
Participants with shock (including cardiogenic shock), or hypovolemia
Severe hypotension (resting SBP<90mmHg，or resting DBP<60mmHg)
Significant valvular heart disease, congenital heart disease or cardiomyopathy
Congestive heart failure(New York Heart Association [NYHA] III-IV), echocardiographic ejection fraction<45%
Acute pulmonary edema;

Hepatic or renal dysfunction, defined as:

Serum Alanine Aminotransferase (ALT) > triple of the normal value upper limit;
Serum Aspartate Aminotransferase (AST) > triple of the normal value upper limit
Serum creatinine > twice of the normal value upper limit
Glaucoma
Active peptic ulcer or active skin ulcer
Taking glyburide, phosphodiesterase type 5 (PDE-5) inhibitor, soluble guanylate cyclase stimulator(s)
Known to be hypersensitivity to nicorandil, nitrates, niacin, or any of the excipient
With contraindication to complete stress PET test
No legal ability and legal ability is limited
Participants unlikely to cooperate in the study or with inability or unwillingness to give informed consent
Child-bearing period women without effective contraceptive measures, pregnancy and lactation
Participation in another clinical trial within the past 30 days
Other significant disease that in the Investigator's opinion would exclude the participant from the trial
Intervention: Victoza
Trial phase: Not Applicable
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection
Eligibility criteria:
Inclusion Criteria:

Patients with type 2 diabetes mellitus (T2DM) without coronary artery disease (CAD)
Patients with T2DM and CAD.
Obese patients (BMI >30 Kg/m²) with abnormal oral glucose tolerance test (OGTT)

Exclusion Criteria:

valvular heart disease
congestive heart failure
peripheral vascular disease
liver or kidney failure
history of alcohol or drug abuse
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 126
Group description: Oxytocin 100 micrograms administered intrathecally

Oxytocin: spinal injection of oxytocin
Eligibility criteria:
Inclusion Criteria:

Scheduled for unilateral, primary total hip replacement
American Society of Anesthesiologists physical status 1-3

Exclusion Criteria:

Pregnancy
Currently Workman's Comp litigation related to hip replacement
Taking greater than 100 milligrams of morphine (or equivalent)
Suffering from a psychotic disorder or a recent psychiatric hospitalization
Intervention: Ibuprofen
Trial phase: Not Applicable
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 202
Group description: This arm will be assigned a postpartum analgesic regimen with ibuprofen.

Ibuprofen: Participants will receive ibuprofen for postpartum mild pain relief
Eligibility criteria:
Inclusion Criteria:

Delivery occurred at equal to or greater than 24 0/7 weeks gestational age
Patient receiving care with the Women's Perinatal Group (Maternal Fetal Medicine practice) or Obstetric Clinic resident services
Diagnosis of a hypertensive disorder of pregnancy (HDP), including the following:
Gestational hypertension
Preeclampsia without severe features
Preeclampsia with severe features
Hemolysis, Elevated Liver Enzymes, Low Platelet (HELLP) Syndrome
Eclampsia

Exclusion Criteria:

Diagnosis of chronic hypertension or documentation of elevated blood pressures before 20 weeks gestational age.
Severe hypertension: Patients with at least one severe blood pressure measurement (systolic >160mmHg or diastolic >105mmHg) prior to randomization
Renal dysfunction (Serum creatinine measurement >1.3mg/dL during the current pregnancy)
Low platelet count (recorded measurement <50,000 during hospital admission)
Significant liver dysfunction (AST or ALT >500)
Known sensitivities to ibuprofen or acetaminophen
Use of therapeutic doses of anticoagulation (low dose anticoagulation used for routine prophylaxis of venous thromboembolism is acceptable)
Postpartum hemorrhage requiring transfusion
Intervention: Lorazepam
Trial phase: Phase 4
ATC code: N05BA06 | N05BA56
SMILES: O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 42
Group description: Patients received a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.

Benzodiazepines: Benzodiazepines administered using a symptoms triggered protocol
Eligibility criteria:
Inclusion criteria

Prediction of Alcohol Withdrawal Severity Scale (PAWSS) score >4.
Adults age 18 or older.
Sufficient understanding of English.
Hospitalized on Hospital Internal Medicine or Generose.

Exclusion criteria

Severe renal impairment (estimated CrCl < 30).
Intensive Care Unit (ICU) level of care.
Not responsive due to alcohol intoxication or withdrawal.
Already taking gabapentin more than 300 mg three times a day.
Prescribed pregabalin.
Primary seizure disorder.
Acute benzodiazepine withdrawal.
Concurrent substance use disorders (such as opioid use disorder, stimulant use disorder) if the disorder is assessed to be clinically significant. Cannabis use disorder will be allowed.
Concurrent anticonvulsant medications for psychiatric indications (e.g. bipolar disorder) will be allowed.
Pregnancy.
Involuntary legal status (e.g., on court commitment).
Patients admitted greater than 12 hours prior to potential enrollment.
Patients receiving therapeutic dose of gabapentin (rather than continuation of home dose) prior to enrollment.
Intervention: Trelagliptin
Trial phase: Phase 4
SMILES: Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
Eligibility criteria:
Inclusion Criteria:

Participants diagnosed as type 2 diabetes.
Participants with a stable diet and exercise therapy only for at least 12 weeks prior to the start of the screening period.
Participants who require a DPP-4 inhibitor treatment.
Participants with Hemoglobin A1c (HbA1c) >=6.5 % and <10.0 % at the start of the screening period.
Participants who completed DTR-QOL questionnaire at the start of the screening period.
Participants who have received less than 2 types of medication for treatment of comorbidities (such as hypertension or dyslipidemia) at the start of the screening period (any number of daily doses).
Participants who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical study and complying with the study protocol requirements.
Participants who can provide the written informed consent prior to the initiation of any study procedures.
Participants aged >=20 years at the time of informed consent.
Outpatient.

Exclusion Criteria:

Participants who are receiving any oral anti-diabetic medication for the treatment of type 2 diabetes at the start of the screening period.
Participants diagnosed with type 1 diabetes.
Participants with severe renal impairment or renal failure (e.g., estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 or on dialysis).
Participants with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or other disease.
Participants with a history of gastrointestinal resection.
Participant with a proliferative diabetic retinopathy.
Participant with malignancy.
Participants with a history of hypersensitivity or allergy to DPP-4 inhibitors.
Pregnant, lactating or planning pregnancy during the study period.
Participants who may need to add or discontinue concomitant medication or change the dose during the study period.
Participants who will require treatment with a prohibited concomitant medication during the study period.
Participants participating in other clinical studies.
Participants assessed ineligible in the study by the principal investigator or the investigator.
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Oxytocin, to be administered intranasally twice daily for six weeks. TSST will be conducted prior to study drug administration and after the 6-week course.
Eligibility criteria:
Inclusion Criteria:

At least 18 years old
Enrolled as a patient who at the SFVAMC Opioid Treatment Program or the Oakland Behavioral Health Clinic Opioid Treatment Program
Stable dose of opioid replacement therapy for at least 2 consecutive weeks
Veteran
One documented urine toxicology screen positive for stimulants in the past 12 months.

Exclusion Criteria:

Severe neuropsychological disorder
Suicidal or homicidal ideation within the past 90 days or a suicide attempt in the past 6 months
Hemodialysis, unless participant can produce urine samples weekly
Sensitivity to methylparaben or propylparaben
Positive urine pregnancy test or women of childbearing age not practicing effective means of non-hormonal birth control
Chronic nasal obstruction, discharge, or bleeding
Intervention: Prepopik
Trial phase: Phase 3
SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O.O=S(=O)([O-])Oc1ccc(C(c2ccc(OS(=O)(=O)[O-])cc2)c2ccccn2)cc1.O=[Mg].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 453
Group description: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder

Supplied as two packets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Eligibility criteria:
Inclusion Criteria:

Male or non-pregnant female subjects aged 18 to 80 years, inclusive, being scheduled to undergo elective colonoscopy
Females of childbearing potential must agree to use an adequate contraception during the course of the trial. Accepted forms of contraception are: i.e., implants, injectables, hormonal intrauterine device, combined hormonal contraceptives, sexual abstinence, and vasectomized sexual partner. Premenopausal women who are of childbearing potential must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at randomization prior to colonoscopy. In the case of oral contraceptive use, women should have been taking the same pill consistently for a minimum of twelve (12) weeks before taking study medication. Sterilized or postmenopausal women may also participate. Women are considered to be postmenopausal and are not considered to be of childbearing potential if they have had twelve (12) months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation.
An average of at least 3 spontaneous bowel movements per week for one month prior to the colonoscopy

Exclusion Criteria:

Known or suspected gastrointestinal obstruction, perforation, ileus, or gastric retention
Acute intestinal or gastric ulceration
Severe acute inflammatory bowel disease (IBD), toxic colitis, or toxic megacolon
Undergoing colonoscopy for foreign body removal or decompression
Reduced level of consciousness or inability to swallow without aspiration
Any prior colorectal surgery, excluding appendectomy, hemorrhoid surgery, or prior endoscopic procedures
Upper gastrointestinal surgery (gastrectomy, gastric banding, gastric by-pass)
Uncontrolled angina and/or myocardial infarction (MI) within last three months, congestive heart failure (CHF), uncontrolled hypertension, or ascites
Severely reduced renal function (<30 mL/min/1.73 m2)
Pregnant or lactating women
Any clinically relevant abnormal findings in medical history, physical examination, vital signs, ECG, clinical chemistry, hematology, coagulation, or urinalysis at Screening Visit 1
Rhabdomyolysis
Chronic nausea and vomiting
Hypermagnesemia
Undergoing treatment with Lithium